Literature DB >> 30048602

Evaluating the Completeness of ClinicalTrials.gov.

Stella Stergiopoulos1, Kenneth A Getz1, Christine Blazynski2.   

Abstract

BACKGROUND: To date, although studies have been conducted to assess compliance with listing clinical trial information, to our knowledge there is nothing in the literature examining the completion and accuracy of clinical trial site information on ClinicalTrials.gov .
METHODS: We compared clinical trial information originating from ClinicalTrials.gov to a widely subscribed and well-established commercial clinical trial database, Informa Pharma Intelligence's Trialtrove, as Trialtrove includes information from ClinicalTrials.gov among its more than 30,000 sources. We assessed breast cancer, non-small cell lung cancer, type 2 diabetes mellitus, and pain clinical trials submitted to ClinicalTrials.gov . We compared the number of trials associated with each disease indication for each database, and we conducted a head-to-head comparison of certain data fields of clinical trial information found in both databases for clinical trials with identical National Clinical Trial (NCT) numbers.
RESULTS: As of January 17, 2017, Trialtrove captured 31% more clinical trials (10,786 trials) in the selected disease indications than did ClinicalTrials.gov (7,419 trials) using identical Medical Subject Headings (MeSH) terms for breast cancer, non-small cell lung cancer, type 2 diabetes mellitus, and pain. Clinical trial site information was identical in 48% of clinical trials, while country information was identical in 82% of clinical trials, and patient enrollment figures identical for 86% of clinical trials. Clinical trial status, Phase, and start year differed across the 2 datasets.
CONCLUSION: This study provides a baseline to compare the completeness of trial information required by the NIH and HHS with respect to reporting practices on ClinicalTrials.gov . While one cannot determine which database is more accurate: ClinicalTrials.gov or Trialtrove, wide variation exists in clinical trial site and country information for trials with identical NCT numbers suggesting that caution should be used when relying solely on ClinicalTrials.gov to assess the clinical trial landscape.

Entities:  

Keywords:  ClinicalTrials.gov; clinical trial competitive intelligence; clinical trial design; clinical trial site selection; country selection; research data resources

Year:  2018        PMID: 30048602     DOI: 10.1177/2168479018782885

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  6 in total

1.  Sharing of Individual Participant Data from Clinical Trials: General Comparison and HIV Use Case.

Authors:  Craig S Mayer; Nick Williams; Sigfried Gold; Kin Wah Fung; Vojtech Huser
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

2.  Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points.

Authors:  Antoni Torres; Doug Rank; David Melnick; Ludmyla Rekeda; Xiang Chen; Todd Riccobene; Ian A Critchley; Hassan D Lakkis; Dianna Taylor; Angela K Talley
Journal:  Open Forum Infect Dis       Date:  2019-04-25       Impact factor: 3.835

3.  Prototypical Clinical Trial Registry Based on Fast Healthcare Interoperability Resources (FHIR): Design and Implementation Study.

Authors:  Christian Gulden; Romina Blasini; Azadeh Nassirian; Alexandra Stein; Fatma Betül Altun; Melanie Kirchner; Hans-Ulrich Prokosch; Martin Boeker
Journal:  JMIR Med Inform       Date:  2021-01-12

4.  Impact of the COVID-19 pandemic on the conduct of clinical trials: a quantitative analysis.

Authors:  Wojciech Margas; Piotr Wojciechowski; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2022-08-09

5.  The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.

Authors:  Luqmaan Mohamed; Siddhi Manjrekar; Derek P Ng; Alec Walsh; Gilberto Lopes; Jayson L Parker
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

6.  Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.

Authors:  Gabrielle W Peters; Weiwei Tao; Wei Wei; Joseph A Miccio; Krishan R Jethwa; Michael Cecchini; Kimberly L Johung
Journal:  Oncologist       Date:  2021-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.